Anixa Biosciences Inc(ANIX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:08 PM ET (Korea 10/31 08:08)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.31 | Insider Own | 5.62% | Shs Outstand | 34.6M | Perf Week | 4.35% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | -1.06% | Insider Trans | 9.25% | Shs Float | 32.8M | Perf Month | 12.64% |
| Enterprise Value | 0.09B | PEG | - | EPS next Q | -0.08 | Inst Own | 15.47% | Short Float | 5.06% | Perf Quarter | -8.5% |
| Income | -0.01B | P/S | - | EPS this Y | 7.84% | Inst Trans | 1.26% | Short Ratio | 6 | Perf Half Y | -0.64% |
| Sales | 0.00B | P/B | 7.46 | EPS next 5Y | 0.99% | ROA | -63.45% | Short Interest | 1.66M | Perf YTD | - |
| Book/sh | 0.42 | P/C | 7.83 | EPS past 3/5Y | 9.05% 5.67% | ROE | -66.84% | 52W High | -42.82% ($5.46) | Perf Year | -23.15% |
| Cash/sh | 0.4 | P/FCF | - | Sales past 3/5Y | - | ROIC | -71.11% | 52W Low | 34.48% ($2.32) | Perf 3Y | -2.19% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 10.04% | Gross Margin | - | Volatility(W/M) | 7.33% 5.95% | Perf 5Y | -34.59% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.18 | Perf 10Y | -53.78% |
| Dividend Ex-Date | - | Quick Ratio | 8.54 | EPS Q/Q | -9.64% | Profit Margin | - | RSI (14) | 56.28 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.54 | Sales Q/Q | - | SMA20 | 7.37% ($2.91) | Beta | 0.49 | Target Price | $9.67 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/09/11 | SMA50 | 4.97% ($2.97) | Rel Volume | 0.51 | Prev Close | $3.3 |
| Employees | 4 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | 5.15% ($2.97) | Avg Volume(3M) | 0.28M | Price | $3.12 |
| IPO | 1983/10/7 | Option/Short | Yes/Yes | Trades | 611 | Volume | 140,662 | Change | -5.45% |
🧬 Adagca BioSciences is a U.S. clinical-stage biotech company focused on cancer treatment and prevention. The company develops a breast cancer vaccine candidate and a cell therapy program targeting ovarian cancer through research partnerships, and is strategically positioned to pursue an immune-based approach to address unmet medical needs.
Over the past 1 year, roughly in the middle
43% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
ANIX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.8% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -34.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 15.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #347 of 597 in the industry
Based on market cap of $108M.
NERV#344 Minerva Neurosciences Inc $111M PER - 
AVXL#345 Anavex Life Sciences Corp $110M PER - 
PYPD#346 Polypid Ltd $109M PER - ANIX#347 Anixa Biosciences Inc $108M PER - 
OKUR#348 OnKure Therapeutics Inc $106M PER - 
FAQ
What kind of company is ANIX?
ANIX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANIX?
The market cap of ANIX is approximately $108M, ranking 4,416 within its sector.
What is the 52-week high and low for ANIX?
ANIX has recorded a 52-week high of $5.46 and a low of $2.32.
